デフォルト表紙
市場調査レポート
商品コード
994141

融合タンパク質の世界市場

Fusion Proteins

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 131 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

融合タンパク質の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 131 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の融合タンパク質の市場規模は、分析期間(2020年~2027年)に4.8%のCAGRで成長する見通しで、2020年の209億米ドルから、2027年には291億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つである代謝障害は、分析期間中に5.5%のCAGRで成長し、87億米ドルに達すると予測されています。

当レポートは、世界の融合タンパク質市場について調査しており、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Abnova
  • Absolute Antibody
  • Amgen Science
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Chimerigen
  • Genzyme
  • Ligand Pharmaceuticals
  • NOVUS
  • Peprotech
  • ProSpec
  • Regeneron
  • Roche
  • Viventia;

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と成長要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:32社
目次
Product Code: MCP17413

Abstract:

Global Fusion Proteins Market to Reach $29.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Fusion Proteins estimated at US$20.9 Billion in the year 2020, is projected to reach a revised size of US$29.1 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Metabolic Disorders, one of the segments analyzed in the report, is projected to record a 5.5% CAGR and reach US$8.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Immunological Disorders segment is readjusted to a revised 5.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $6.2 Billion, While China is Forecast to Grow at 4.5% CAGR

The Fusion Proteins market in the U.S. is estimated at US$6.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.1 Billion by the year 2027 trailing a CAGR of 4.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Hematological Disorders Segment to Record 4.9% CAGR

In the global Hematological Disorders segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.7 Billion in the year 2020 will reach a projected size of US$3.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.3 Billion by the year 2027.

Select Competitors (Total 32 Featured) -

  • Abnova
  • Absolute Antibody
  • Amgen Science
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Chimerigen
  • Genzyme
  • Ligand Pharmaceuticals
  • NOVUS
  • Peprotech
  • ProSpec
  • Regeneron
  • Roche
  • Viventia;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Fusion Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Fusion Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Fusion Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Immunological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Hematological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Hematological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Hematological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Hormonal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 25: USA Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 28: Canada Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 31: Japan Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 34: China Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: China Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: China 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 37: Europe Current & Future Analysis for Fusion Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 38: Europe Historic Review for Fusion Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Europe 15-Year Perspective for Fusion Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 40: Europe Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Europe Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Europe 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 43: France Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: France Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: France 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 46: Germany Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Germany Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Germany 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 49: Italy Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Italy Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Italy 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 52: UK Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: UK Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: UK 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 55: Rest of Europe Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Rest of Europe Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Rest of Europe 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 58: Asia-Pacific Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Asia-Pacific Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Asia-Pacific 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 61: Rest of World Current & Future Analysis for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Rest of World Historic Review for Fusion Proteins by Application - Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Rest of World 15-Year Perspective for Fusion Proteins by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 32